FDA Inspection 1267158 — Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd.
The FDA completed an inspection of Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd. on March 7, 2025 in Wuhan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 7, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)